{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:29Z","timestamp":1792784849978,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MultiVir Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While immune checkpoint inhibitors are becoming a standard of care for multiple types of cancer, the majority of patients do not respond to this form of immunotherapy. New approaches are required to overcome resistance to immunotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated the effects of adenoviral p53 (Ad-p53) gene therapy in combination with immune checkpoint inhibitors and selective IL2 or IL15 CD122\/132 agonists in the aggressive B16F10 tumor model resistant to immunotherapies. To assess potential mechanisms of action, pre- and post- Ad-p53 treatment biopsies were evaluated for changes in gene-expression profiles by Nanostring IO 360 assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The substantial synergy of \u201ctriplet\u201d Ad-p53\u2009+\u2009CD122\/132\u2009+\u2009anti-PD-1 therapy resulted in potential curative effects associated with the complete tumor remissions of both the primary and contralateral tumors. Interestingly, contralateral tumors, which were not injected with Ad-p53 showed robust abscopal effects resulting in statistically significant decreases in tumor size and increased survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). None of the monotherapies or doublet treatments induced the complete tumor regressions. Ad-p53 treatment increased interferon, CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell, immuno-proteosome antigen presentation, and tumor inflammation gene signatures. Ad-p53 treatment also decreased immune-suppressive TGF-beta, beta-catenin, macrophage, and endothelium gene signatures, which may contribute to enhanced immune checkpoint inhibitor (CPI) efficacy. Unexpectedly, a number of previously unidentified, strongly p53 downregulated genes associated with stromal pathways and IL10 expression identified novel anticancer therapeutic applications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results imply the ability of Ad-p53 to induce efficacious local and systemic antitumor immune responses with the potential to reverse resistance to immune checkpoint inhibitor therapy when combined with CD122\/132 agonists and immune checkpoint blockade. Our findings further imply that Ad-p53 has multiple complementary immune mechanisms of action, which support future clinical evaluation of triplet Ad-p53, CD122\/132 agonist, and immune checkpoint inhibitor combination treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41417-021-00369-7","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:41:16Z","timestamp":1628120476000},"page":"825-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Tumor suppressor immune gene therapy to reverse immunotherapy resistance"],"prefix":"10.1038","volume":"29","author":[{"given":"Sunil","family":"Chada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Wiederhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin B.","family":"Menander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatha","family":"Sellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Talbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-2381","authenticated-orcid":false,"given":"John J.","family":"Nemunaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-7662","authenticated-orcid":false,"given":"Bo-Kyeong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-4531","authenticated-orcid":false,"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-5758","authenticated-orcid":false,"given":"Robert E.","family":"Sobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"369_CR1","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535.","journal-title":"JAMA Netw Open."},{"key":"369_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19:694\u2013704.","journal-title":"Lancet Oncol."},{"key":"369_CR3","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","volume":"10","author":"A Diab","year":"2020","unstructured":"Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, et al. Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov. 2020;10:1158\u201373.","journal-title":"Cancer Discov."},{"key":"369_CR4","first-page":"2597","volume":"53","author":"G Ju","year":"1993","unstructured":"Ju G, Heaton KM, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine Secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 1993;53:2597\u2013602.","journal-title":"Cancer Res."},{"key":"369_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019. Nature. 2012;484:529\u201333.","journal-title":"Nature."},{"key":"369_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","volume":"4","author":"PR Rhode","year":"2016","unstructured":"Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 2016;4:49\u201360.","journal-title":"Cancer Immunol Res."},{"key":"369_CR7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22:680\u201390.","journal-title":"Clin Cancer Res."},{"key":"369_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cgt.2008.69","volume":"16","author":"M Olivier","year":"2009","unstructured":"Olivier M, Petitjean A, Marcel V, P\u00e9tr\u00e9 A, Mounawar M, Plymoth A, et al. Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Ther. 2009;16:1\u201312.","journal-title":"Cancer Gene Ther"},{"key":"369_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/mc.2940140408","volume":"14","author":"RA Gjerset","year":"1995","unstructured":"Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, et al. Use of wild\u2010type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinogenesis. 1995;14:275\u201385.","journal-title":"Mol Carcinogenesis."},{"key":"369_CR10","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.1158\/1078-0432.CCR-09-1044","volume":"15","author":"J Nemunaitis","year":"2009","unstructured":"Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res. 2009;15:7719\u201325.","journal-title":"Clin Cancer Res."},{"key":"369_CR11","first-page":"5","volume":"1","author":"WW Zhang","year":"1994","unstructured":"Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5\u201313.","journal-title":"Cancer Gene Ther"},{"key":"369_CR12","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1158\/1535-7163.MCT-07-0125","volume":"6","author":"N Senzer","year":"2007","unstructured":"Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H, et al. p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Therapeutics. 2007;6:1478\u201382.","journal-title":"Mol Cancer Therapeutics."},{"key":"369_CR13","doi-asserted-by":"crossref","unstructured":"Sobol RE, Guan YS, Li LJ, Zhang WW, Peng Z, Menander KB, et al. Tp53 gene therapy for cancer treatment and prevention. New York: Springer; 2013. p. 189\u2013208.","DOI":"10.1007\/978-1-4614-3676-8_11"},{"key":"369_CR14","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","volume":"180","author":"S Dubois","year":"2008","unstructured":"Dubois S, Patel HJ, Zhang M, Waldmann TA, M\u00fcller JR. Preassociation of IL-15 with IL-15R$\u03b1$-IgG1-Fc enhances its activity on proliferation of NK and CD8 + \/CD44 high T cells and its antitumor action. J Immunol. 2008;180:2099\u2013106.","journal-title":"J Immunol."},{"key":"369_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4049\/jimmunol.1600019","volume":"197","author":"M Desbois","year":"2016","unstructured":"Desbois M, Le VuP, Coutzac C, Marcheteau E, B\u00e9al C, Terme M, et al. IL-15 Trans -signaling with the superagonist RLI promotes effector\/memory CD8 + T cell responses and enhances antitumor activity of PD-1 antagonists. J Immunol. 2016;197:168\u201378.","journal-title":"J Immunol."},{"key":"369_CR16","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1158\/1078-0432.CCR-10-2921","volume":"17","author":"SD Gillies","year":"2011","unstructured":"Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y, Mueller SO, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res. 2011;17:3673\u201385.","journal-title":"Clin Cancer Res."},{"key":"369_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0367-1","volume":"6","author":"P Danaher","year":"2018","unstructured":"Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, et al. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018;6:1\u201317.","journal-title":"J Immunother Cancer."},{"key":"369_CR18","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Ribas A, McClanahan TK, Ayers M, Lunceford J, Nebozhyn M, et al. blockade IFN- $\u03b3$ \u2013 related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127:2930\u201340.","journal-title":"J Clin Investig."},{"key":"369_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17305\/bjbms.2015.783","volume":"15","author":"SH Dzinic","year":"2015","unstructured":"Dzinic SH, Bernardo MM, Oliveira DSM, Wahba M, Sakr W, Sheng S. Tumor suppressor maspin as a modulator of host immune response to cancer. Bosn J Basic Med Sci. 2015;15:1\u20136.","journal-title":"Bosn J Basic Med Sci"},{"key":"369_CR20","doi-asserted-by":"publisher","first-page":"11225","DOI":"10.18632\/oncotarget.2615","volume":"5","author":"SH Dzinic","year":"2014","unstructured":"Dzinic SH, Chen K, Thakur A, Kaplun A, Daniel Bonfil R, Li X, et al. Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget. 2014;5:11225\u201336.","journal-title":"Oncotarget."},{"key":"369_CR21","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/j.1349-7006.2008.00924.x","volume":"99","author":"RJA Fijneman","year":"2008","unstructured":"Fijneman RJA, Peham JR, van de Wiel MA, Meijer GA, Matise I, Velcich A, et al. Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice. Cancer Sci. 2008;99:2113\u20139.","journal-title":"Cancer Sci."},{"key":"369_CR22","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1158\/0008-5472.CAN-07-6517","volume":"68","author":"K Ganesan","year":"2008","unstructured":"Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Ming HL, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel $\u03b2$-catenin\/TCF target gene. Cancer Res. 2008;68:4277\u201386.","journal-title":"Cancer Res."},{"key":"369_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF-\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature."},{"key":"369_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic $\u03b2$-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature."},{"key":"369_CR25","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.3892\/or.2017.5626","volume":"37","author":"A Dou","year":"2017","unstructured":"Dou A, Wang Z, Zhang N, Liu J. Loss of reelin suppresses cell survival and mobility in non-Hodgkin lymphoma. Oncol Rep. 2017;37:3572\u201380.","journal-title":"Oncol Rep."},{"key":"369_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.immuni.2015.05.021","volume":"42","author":"JJ Garcia-Vallejo","year":"2015","unstructured":"Garcia-Vallejo JJ, van Kooyk Y. DC-SIGN: the strange case of Dr. Jekyll and Mr. Hyde. Immunity. 2015;42:983\u20135.","journal-title":"Immunity"},{"key":"369_CR27","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.celrep.2016.04.084","volume":"15","author":"AM Georgoudaki","year":"2016","unstructured":"Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, \u00d6stling J, et al. Reprogramming yumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15:2000\u201311.","journal-title":"Cell Rep."},{"key":"369_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v9070175","volume":"9","author":"I Mart\u00ednez-Ram\u00edrez","year":"2017","unstructured":"Mart\u00ednez-Ram\u00edrez I, Del-Castillo-Falconi V, Mitre-Aguilar IB, Amador-Molina A, Carrillo-Garc\u00eda A, Langley E, et al. SOX2 as a new regulator of HPV16 transcription. Viruses. 2017;9:1\u201317.","journal-title":"Viruses."},{"key":"369_CR29","doi-asserted-by":"publisher","first-page":"645745.","DOI":"10.3389\/fonc.2021.645745","volume":"11","author":"RE Sobol","year":"2021","unstructured":"Sobol RE, Menander KB, Chada S, Wiederhold D, Sellman B, Talbott M, et al. Analysis of adenoviral p53 gene therapy clinical trials in recurrent head and neck squamous cell carcinoma. Front Oncol. 2021;11:645745.","journal-title":"Front Oncol"},{"key":"369_CR30","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/jco.2015.33.15_suppl.3001","volume":"33","author":"A Ribas","year":"2015","unstructured":"Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol. 2015;33:3001.","journal-title":"J Clin Oncol"},{"key":"369_CR31","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.neo.2018.09.007","volume":"20","author":"AK Brenner","year":"2018","unstructured":"Brenner AK, Bruserud \u00d8. S100 proteins in acute myeloid leukemia. Neoplasia. 2018;20:1175\u201386.","journal-title":"Neoplasia"},{"key":"369_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","volume":"173","author":"A Prasse","year":"2006","unstructured":"Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respiratory Crit Care Med. 2006;173:781\u201392.","journal-title":"Am J Respiratory Crit Care Med."},{"key":"369_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1371\/journal.pmed.0050062","volume":"5","author":"M Selman","year":"2008","unstructured":"Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 2008;5:373\u201380.","journal-title":"PLoS Med"},{"key":"369_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1183\/09059180.00010908","volume":"17","author":"MP Keane","year":"2008","unstructured":"Keane MP. The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev. 2008;17:151\u20136.","journal-title":"Eur Respir Rev"},{"key":"369_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00251-012-0604-6","volume":"64","author":"NM Korthagen","year":"2012","unstructured":"Korthagen NM, Van Moorsel CHM, Kazemier KM, Ruven HJT, Grutters JC. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics. 2012;64:371\u20137.","journal-title":"Immunogenetics."},{"key":"369_CR36","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/0008-5472.CAN-16-2219","volume":"77","author":"SH Dzinic","year":"2017","unstructured":"Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, et al. An essential role of maspin in embryogenesis and tumor suppression. Cancer Res. 2017;77:886\u201396.","journal-title":"Cancer Res."},{"key":"369_CR37","first-page":"6389","volume":"9","author":"UG Sathyanarayana","year":"2003","unstructured":"Sathyanarayana UG, Padar A, Huang CX, Suzuki M, Shigematsu H, Bekele BN, et al. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. Clin Cancer Res. 2003;9:6389\u201394.","journal-title":"Clin Cancer Res."},{"key":"369_CR38","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1038\/sj.onc.1209740","volume":"25","author":"Y Huang","year":"2006","unstructured":"Huang Y, Li X, Jiang J, Frank SJ. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene. 2006;25:7565\u201376.","journal-title":"Oncogene."},{"key":"369_CR39","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.2174\/1389557514666141127142301","volume":"14","author":"J Segovia","year":"2014","unstructured":"Segovia J, Zarco N. Gas1 is a pleiotropic regulator of cellular functions: from embryonic development to molecular actions in cancer gene therapy. Mini-Rev Medicinal Chem. 2014;14:1139\u201347.","journal-title":"Mini-Rev Medicinal Chem"},{"key":"369_CR40","doi-asserted-by":"publisher","first-page":"e15099.","DOI":"10.7554\/eLife.15099","volume":"5","author":"X Zhou","year":"2016","unstructured":"Zhou X, Hao Q, Liao P, Luo S, Zhang M, Hu G, et al. Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. eLife. 2016;5:e15099.","journal-title":"eLife"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00369-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T19:04:43Z","timestamp":1655751883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00369-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1038\/s41417-021-00369-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.12.27.20248913","asserted-by":"object"}]},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.E.S., S.C., K.B.M., M.T., B.S. and D.W. had consulting relationships with MultiVir Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies involving human participants were reviewed and approved by the ethics committee of the University of Toledo. The patients\/participants provided their written informed consent to participate in this study.All mice-related experiments were performed under an approved protocol following the institutional guidelines established by the institutional animal care and use committee (IACUC) of Hanyang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}